In Good Company Program
Phenylketonuria (PKU) & Inherited Metabolic Diseases
Key Facts
About Navamedic
Navamedic's mission is to be a reliable supplier of high-quality pharmaceutical products and medical nutrition, focusing on niche therapeutic areas with unmet needs. The company has achieved consistent growth, reporting 2025 revenue of MNOK 565.4 and a profitable EBITDA of MNOK 47.6, supported by a portfolio of ~50 brands. Its strategy centers on a capital-efficient, commercial-stage model: in-licensing or acquiring approved or near-approved products, then leveraging its established Nordic regulatory, distribution, and market access expertise for launch and lifecycle management. A key strategic pillar is building deep patient community relationships, exemplified by its 'In Good Company' support program for metabolic diseases.
View full company profile